Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies (mAbs) and fusion proteins directed towards soluble targets make an important contribution to the treatment of disease. The purpose of this review was to correlate the clinical and preclinical data on the 14 currently approved mAbs and fusion proteins targeted to soluble targets. The principal sources used to gather data were: the peer reviewed Literature; European Medicines Agency ‘Scientific Discussions’ and United States Food and Drug Administration ‘Pharmacology/Toxicology Reviews’ and package inserts (United States Prescribing Information). Data on the following approved biopharmaceuticals were included: adalimumab, anakinra, bevacizumab, canakinumab, certolizumab pegol, denosumab, eculizumab, etanercept, golimumab, infliximab, omalizumab, ranibizumab, rilonacept and ustekinumab. Some related biopharmaceuticals in late‐stage development were also included for comparison. Good concordance with human pharmacodynamics was found for both non‐human primates (NHPs) receiving the human biopharmaceutical and mice receiving rodent homologues (surrogates). In contrast, there was limited concordance for human adverse effects in genetically deficient mice, mice receiving surrogates or NHPs receiving the human pharmaceutical. In summary, the results of this survey show that although both mice and NHPs have good predictive value for human pharmacodynamics, neither species have good predictive value for human adverse effects. No evidence that NHPs have superior predictive value was found.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515 · cited 1×
“Receptor activator of NF-kB ligand (RANK-L) is a transmembrane or soluble protein essential for the formation, function and survival of osteoclasts (Khosla, 2001).”
BackgroundIL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018 · cited 2×
“In breast cancer tumour-bearing mice, treatment with an anti-murine IL-12/23 p40 antibody produced an increase in the growth of the tumours (Langowski et al., 2006).”
BackgroundIL-1 pathways in inflammation and human diseases
Gabay, C., Lamacchia, C., & Palmer, G. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2010.4 · Cited by 897
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
The effect of a single dose of osteoprotegerin in postmenopausal women.
Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484
Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., et al. (2003) · Cancer · doi:10.1002/cncr.11138 · Cited by 383
A toxicity profile of osteoprotegerin in the cynomolgus monkey.
Smith, B. B., Cosenza, M. E., Mancini, A., Dunstan, C., Gregson, R., Martin, S. W., Smith, S. Y., & Davis, H. (2003) · International Journal of Toxicology · doi:10.1177/109158180302200512 · Cited by 33 · cited 2×
“…a reduction in bone turnover and no effects on infection or inflammation in rodents (Stolina et al., 2007; Ferrari-Lacraz and Ferrari, 2011) and decreases in serum calcium and increases in cortical and trabecular bone without signs of toxicity in monkeys (Smith et al., 2003; Ominsky et al., 2007).”
Background
Cited by
Deng, R., Bumbaca, D., Pastuskovas, C. V., Boswell, C. A., West, D., Cowan, K. J., Chiu, H., McBride, J., Johnson, C., Xin, Y., et al. (2016) · mAbs · doi:10.1080/19420862.2015.1136043 · Cited by 199
“It has been shown that surrogate antibodies in rodents and human antibodies in monkeys display 100% concordance with human PD.(15,16) The nonlinear (dose–dependent) PK of anti-PD-L1 molecules due to TMDD resulting from binding to its endogenous targets in both mice and monkeys was expected.”
BackgroundTamaki, C., Nagayama, T., Hashiba, M., Fujiyoshi, M., Hizue, M., Kodaira, H., Nishida, M., Suzuki, K., Takashima, Y., Ogino, Y., et al. (2013) · The Journal of Toxicological Sciences · doi:10.2131/jts.38.581 · Cited by 79
Brennan, F. R., Cavagnaro, J., McKeever, K., Ryan, P. C., Schutten, M. M., Vahle, J., Weinbauer, G. F., Marrer-Berger, E., & Black, L. E. (2018) · mAbs · doi:10.1080/19420862.2017.1389364 · Cited by 70
Polson, A. G., & Fuji, R. N. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01916.x · Cited by 66
Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015) · Toxicologic Pathology · doi:10.1177/0192623315570340 · Cited by 35
“This reaffirms the often held contention that clinical immunemediated reactions are hard to predict from preclinical data (Bugelski and Tracy 2004; Martin and Bugelski 2012).”
Background
Metadata
- Authors
- Martin, P. L., & Bugelski, P. J.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2012-05-08
- Volume
- 166
- Issue
- 3
- Pages
- 806-822
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1557552070
- Cited by
- 54
- References
- 7
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01812.x
- The paper
- Martin, P. L., & Bugelski, P. J. (2012). Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01812.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.